KR20170102571A - 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법 - Google Patents

오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법 Download PDF

Info

Publication number
KR20170102571A
KR20170102571A KR1020177024247A KR20177024247A KR20170102571A KR 20170102571 A KR20170102571 A KR 20170102571A KR 1020177024247 A KR1020177024247 A KR 1020177024247A KR 20177024247 A KR20177024247 A KR 20177024247A KR 20170102571 A KR20170102571 A KR 20170102571A
Authority
KR
South Korea
Prior art keywords
naltrexone
opioid
dose
respiratory depression
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177024247A
Other languages
English (en)
Korean (ko)
Inventor
마이클 제이. 람슨
비레인다르 골리
Original Assignee
알파마 파머슈티컬스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알파마 파머슈티컬스 엘엘씨 filed Critical 알파마 파머슈티컬스 엘엘씨
Publication of KR20170102571A publication Critical patent/KR20170102571A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177024247A 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법 Ceased KR20170102571A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40675210P 2010-10-26 2010-10-26
US61/406,752 2010-10-26
PCT/IB2011/054767 WO2012056402A2 (en) 2010-10-26 2011-10-25 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167003000A Division KR20160017668A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법

Publications (1)

Publication Number Publication Date
KR20170102571A true KR20170102571A (ko) 2017-09-11

Family

ID=45470606

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020177024247A Ceased KR20170102571A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법
KR1020137010558A Ceased KR20130097211A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법
KR1020167003000A Ceased KR20160017668A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020137010558A Ceased KR20130097211A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법
KR1020167003000A Ceased KR20160017668A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법

Country Status (14)

Country Link
US (3) US20140030343A1 (enExample)
EP (1) EP2632442A2 (enExample)
JP (1) JP2013540807A (enExample)
KR (3) KR20170102571A (enExample)
CN (1) CN103189055A (enExample)
AU (1) AU2011322147A1 (enExample)
BR (1) BR112013009267A2 (enExample)
CA (1) CA2814230A1 (enExample)
IL (1) IL225966A0 (enExample)
MX (1) MX2013003832A (enExample)
RU (1) RU2541159C2 (enExample)
SG (1) SG189234A1 (enExample)
WO (1) WO2012056402A2 (enExample)
ZA (1) ZA201302363B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
CN103189055A (zh) * 2010-10-26 2013-07-03 雅来制药有限责任公司 用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法
KR20130124551A (ko) * 2011-02-02 2013-11-14 알파마 파머슈티컬스 엘엘씨 오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
EP3800177B1 (en) 2015-12-22 2025-01-29 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
WO2017180659A1 (en) * 2016-04-11 2017-10-19 Arizona Board Of Regents On Behalf Of University Of Arizona Opioid receptor modulators
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR102810926B1 (ko) 2017-12-20 2025-05-22 퍼듀 퍼머 엘피 남용 억제 황산모르핀 제형
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) * 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
WO2021072055A1 (en) * 2019-10-11 2021-04-15 Board Of Regents, The University Of Texas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
US20230063876A1 (en) * 2020-03-02 2023-03-02 Unm Rainforest Innovations Virus-Like Particle Vaccines for Opioid Drugs
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CN118488840A (zh) 2021-11-02 2024-08-13 依那拉治疗股份有限公司 治疗由非阿片样药剂调节的呼吸抑制的方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013525A1 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
NZ547851A (en) * 2003-12-05 2010-03-26 Carefusion 303 Inc Patient-controlled analgesia with patient monitoring system
EP1931593A4 (en) 2005-10-07 2009-04-22 Univ Florida MULTIPLE COMPONENT NANOPARTICLES FOR MULTIPLEX SIGNALING AND OPTICAL CODING
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
EP2197427A2 (en) * 2007-09-04 2010-06-23 Alpharma, Inc. A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
IT1391530B1 (it) 2008-07-31 2012-01-11 Cyanagen S R L Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione
US8771642B2 (en) 2008-07-31 2014-07-08 Alma Mater Studiorum—Universita' di Bologna Active particles for bio-analytical applications and methods for their preparation
CN103189055A (zh) * 2010-10-26 2013-07-03 雅来制药有限责任公司 用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法

Also Published As

Publication number Publication date
SG189234A1 (en) 2013-05-31
RU2541159C2 (ru) 2015-02-10
CA2814230A1 (en) 2012-05-03
RU2013117274A (ru) 2014-12-10
KR20160017668A (ko) 2016-02-16
ZA201302363B (en) 2014-06-25
US20140030343A1 (en) 2014-01-30
MX2013003832A (es) 2013-10-01
EP2632442A2 (en) 2013-09-04
KR20130097211A (ko) 2013-09-02
AU2011322147A1 (en) 2013-04-18
CN103189055A (zh) 2013-07-03
WO2012056402A2 (en) 2012-05-03
IL225966A0 (en) 2013-06-27
US20170367987A1 (en) 2017-12-28
WO2012056402A3 (en) 2012-10-04
JP2013540807A (ja) 2013-11-07
BR112013009267A2 (pt) 2016-07-26
US20160045449A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
KR20160017668A (ko) 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법
AU2006217870B2 (en) Dosage form containing oxycodone and naloxone
US20140056975A1 (en) Pharmaceutical Composition
KR20130105935A (ko) 요폐의 치료를 위한 아편유사제 길항제의 용도
US20150104519A1 (en) Pharmaceutical Compositions
US20240408078A1 (en) Method of treatment and dosage forms thereof
US20130209584A1 (en) Pharmaceutical formulations of nitrite and uses thereof
AU2008338439A1 (en) Pharmaceutical composition
JP2026506102A (ja) 疼痛緩和に有用なレジメンおよび組成物
AU2019201397A1 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
HK1186970A (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
WO2026035694A1 (en) Cebranopadol useful for preventing or reducing opioid induced respiratory depression
Yaster et al. Opioids in the Management
US20120283283A1 (en) Methods for detecting enhanced risk of opioid-induced hypoxia in a patient
AU2018219999A1 (en) Pharmaceutical composition
AU2014216026A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170829

Application number text: 1020167003000

Filing date: 20160202

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170928

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171201

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180813

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171201

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I